Iowanews Headlines

Ovarian Cancer Companies are Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, and others.

Ovarian Cancer Pipeline constitutes 180+ key companies continuously working towards developing 200+ Ovarian Cancer treatment therapies, analyzes DelveInsight.

Ovarian Cancer Overview:

Ovarian cancer is the deadliest gynecological cancer and the fifth leading cause of death among women overall. Late-stage diagnosis is common, resulting in poor outcomes. Current screening methods, including ultrasound and cancer antigen-125 (CA-125) assays, have limited effectiveness in reducing morbidity or mortality.

Epithelial ovarian cancer is the most common form, with four main histological types: serous, endometrioid, clear cell, and mucinous tumors, as well as rarer types like Brenner and seromucinous tumors. Based on biology and prognosis, ovarian cancer is classified into two subtypes:

– Type I tumors: Include low-grade serous, endometrioid, clear cell, mucinous, Brenner, and seromucinous carcinomas. They generally originate from borderline tumors, are detected early, and have a favorable prognosis. These tumors exhibit low proliferative activity and minimal genetic instability.

– Type II tumors: Include high-grade serous carcinoma, carcinosarcoma, and undifferentiated carcinoma. They arise from serous tubal intraepithelial carcinoma, are typically aggressive, high-grade, and diagnosed at advanced stages. They show rapid progression, significant chromosomal instability, and frequent mutations in the p53 gene.

Type II tumors are more aggressive and lethal than Type I, highlighting the need for improved early detection and treatment strategies.

Request for a detailed insights report on Ovarian Cancer pipeline insights @ https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

“Ovarian Cancer Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Ovarian Cancer Therapeutics Market.

Key Takeaways from the Ovarian Cancer Pipeline Report

• DelveInsight’s Ovarian Cancer pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Ovarian Cancer treatment.

• In November 2025, Clinical-stage biotech IMUNON, Inc. (Nasdaq: IMNN) revealed new data at its R&D Day, highlighting its DNA-based immunotherapy IMNN‑001 for newly diagnosed advanced ovarian cancer. The company reported that in its Phase 2 OVATION 2 trial, IMNN-001 combined with standard chemotherapy achieved a median 13-month overall survival improvement compared to standard of care alone. The presentation also covered early translational data showing tumour microenvironment remodelling and rapid patient-enrolment progress for the ongoing Phase 3 OVATION 3 trial. IMUNON described the therapy as a potential landmark breakthrough in a disease area where frontline treatment outcomes haven’t changed for decades.

• In May 2025, Allarity Therapeutics concluded a Phase II trial for stenoparib (2X-121) after observing significant clinical benefits in earlier trial phases. The company now aims to launch a follow-up trial designed to expedite regulatory submission for stenoparib.

• Key Ovarian Cancer companies such as Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, and others are evaluating new drugs for Ovarian Cancer to improve the treatment landscape.

• Promising Ovarian Cancer pipeline therapies in various stages of development include Atezolizumab, Tisotumab, SON-1010, DS-6000a, and others.

Ovarian Cancer Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Ovarian Cancer Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ovarian Cancer treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Ovarian Cancer market.

Download our free sample page report on Ovarian Cancer pipeline insights

Ovarian Cancer Emerging Drugs

• Atezolizumab: Genentech

Atezolizumab is a humanized IgG1 kappa monoclonal antibody composed of two heavy chains (448 amino acids each) and two light chains (214 amino acids each), produced using Chinese hamster ovary cells. The antibody was specifically modified by substituting asparagine with alanine at position 298 of the heavy chain, removing Fc-effector activity and preventing Fc receptor binding. This engineering yields a non-glycosylated antibody that does not deplete PD-L1–expressing cells in humans. Atezolizumab binds to human PD-L1, blocking its interaction with PD-1 and B7.1 receptors, thereby preventing inhibitory signaling in T cells. The therapy is currently undergoing Phase 3 clinical trials for ovarian cancer.

• Tisotumab Vedotin: Genmab

Tisotumab vedotin, also referred to as HuMax-TF, HuMax®-TF-ADC, or TF-011-MMAE, is an antibody-drug conjugate (ADC) designed to target tissue factor (TF), a protein that plays a key role in tumor growth and angiogenesis. It consists of a monoclonal antibody directed against TF linked to the cytotoxic agent monomethyl auristatin E (MMAE) through a cleavable mc-val-cit-PABC linker (maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl). The therapy is currently being evaluated in Phase 2 clinical trials for the treatment of ovarian cancer.

• SON-1010: Sonnet Biotherapeutics

SON-1010 is a proprietary formulation of native human IL-12 developed using Sonnet’s Fully Human Albumin Binding (FHAB®) platform, designed to specifically target the tumor microenvironment (TME) while enhancing the molecule’s pharmacokinetic (PK) and pharmacodynamic (PD) properties. Sonnet has entered into a Master Clinical Trial and Supply Agreement (MCSA) with Roche, along with related Quality and Safety Agreements, to evaluate the safety and efficacy of SON-1010 in combination with atezolizumab in patients with platinum-resistant ovarian cancer (PROC). The candidate is currently in Phase I/II clinical development for ovarian cancer.

• DS-6000a: Daiichi Sankyo Company (Request for our detailed report to know more about the ovarian cancer emerging drugs)

Ovarian Cancer Companies

Over 180 major companies are actively developing therapies for ovarian cancer. Among them, Genentech stands out with its drug candidates in the most advanced stage of development, Phase III.

DelveInsight’s report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Ovarian Cancer Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Ovarian Cancer Therapies and Key Companies: Ovarian Cancer Clinical Trials and advancements

Ovarian Cancer Pipeline Therapeutic Assessment

• Ovarian Cancer Assessment by Product Type

• Ovarian Cancer By Stage

• Ovarian Cancer Assessment by Route of Administration

• Ovarian Cancer Assessment by Molecule Type

Download Ovarian Cancer Sample report to know in detail about the Ovarian Cancer treatment market @ Ovarian Cancer Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Ovarian Cancer Current Treatment Patterns

4. Ovarian Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Ovarian Cancer Late-Stage Products (Phase-III)

7. Ovarian Cancer Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Ovarian Cancer Discontinued Products

13. Ovarian Cancer Product Profiles

14. Ovarian Cancer Key Companies

15. Ovarian Cancer Key Products

16. Dormant and Discontinued Products

17. Ovarian Cancer Unmet Needs

18. Ovarian Cancer Future Perspectives

19. Ovarian Cancer Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Ovarian Cancer Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/